Other serious but rare adverse effects documented with GLP-1 receptor agonists include acute pancreatitis
Recommendations for weight gain for women with GDM should be individualized based on Institute of Medicine guidelines by pre-pregnancy BMI to prevent excessive gestational weight gain and reduce the risk of LGA [Grade B, Level 2 (297,299)], macrosomia and caesarean sections [Grade B, Level 2 (296,297)]
The studys findings, published online Jan
[1] [3] According to the UK SmPC, dosing starts at 2.5 mg once weekly for 4 weeks, then increases in 2.5 mg increments every 4 weeks until the target dose (5 mg, 7.5 mg, 10 mg, 12.5 mg or 15 mg) is reached, based on individual response and tolerability
In summary, there are evidence, that treatment with GLP-1RAs may prove useful in the treatment of depressive disorders, however, the number of reliable clinical reports concerning this matter remains very low at this point